Merit Financial Group LLC Acquires 14,508 Shares of Boston Scientific Corporation $BSX

Merit Financial Group LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 12.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 134,928 shares of the medical equipment provider’s stock after acquiring an additional 14,508 shares during the period. Merit Financial Group LLC’s holdings in Boston Scientific were worth $14,493,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BSX. Vanguard Group Inc. raised its stake in Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. raised its stake in Boston Scientific by 161.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock valued at $250,757,000 after acquiring an additional 1,536,663 shares during the period. Swedbank AB increased its position in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after buying an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BSX. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday. Truist Financial boosted their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Barclays increased their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average price target of $120.79.

Boston Scientific Stock Performance

NYSE:BSX opened at $97.30 on Friday. The stock’s 50-day simple moving average is $102.93 and its 200 day simple moving average is $102.06. The firm has a market capitalization of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.